sparsentan · Filspari
Small molecule
Evidence outlook
Approved: IgA Nephropathy, Focal Segmental Glomerulosclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PROTECT NCT03762850 · IgA Nephropathy The trial was randomized, double-blind and active-controlled in 406 patients, and the primary comparison was statistically significant. The primary endpoint is the change in urine protein, a laboratory marker of kidney damage and not a kidney-function or kidney-failure outcome. Because the main endpoint is a surrogate marker, the evidence is graded moderate. Registry: NCT03762850 | 3 | Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36 (Baseline (Day 1) and at Week 36) 2023-08-07 | Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36 (Baseline (Day 1) and at Week 36): Sparsentan -49.77 Percent change (95% CI -54.98 to -43.95) | Irbesartan -15.05 Percent change (95% CI -23.72 to -5.39) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) drugs
HS-10390. Compare all 2 Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Focal Segmental Glomerulosclerosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Sparsentan (Filspari): this drug | Approved | Small molecule | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) | Partial signal | No reviewed efficacy summary in this indication | |
| Apecotrep | Phase 3 | Small molecule | TRPC6 (transient receptor potential cation channel subfamily C member 6) | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10390 | Phase 2(overall) | Small molecule | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Praliciguat | Phase 2 | Small molecule | Soluble guanylate cyclase | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Filspari (sparsentan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (3)
March 2027 (2)
December 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent